11.05.2017 • NewsPeopleLanxessChemtura

Stephen Forsyth to Become Chief Integration Officer at Lanxess

Stephen C. Forsyth is to become the new Chief Integration Officer of Lanxess....
Stephen C. Forsyth is to become the new Chief Integration Officer of Lanxess. © Lanxess

German specialty chemicals producer Lanxess has named Stephen C. Forsyth (61) as the future Chief Integration Officer responsible for integrating the Chemtura businesses into the Cologne-based company, effective Jun. 1, 2017. Lanxess acquired the US chemical company in April 2017. The newly created position is limited to one year.

Forsyth has more than 35 years of management experience in the chemical industry. Since 2007 he has acted as EVP and CFO of Chemtura. Prior to that, he worked 27 years for the materials company Hexcel, holding various positions. There, he was appointed CFO in 1996, having previously worked as VP International Operations, heading up the business outside the United States. Forsyth holds an MBA from the London Business School.

Lanxess CEO Matthias Zachert said: “Stephen Forsyth brings exactly the qualities that Lanxess needs for integrating the Chemtura business: he has an excellent knowledge of the new businesses and employees and can also draw on longstanding experience in company transformation processes.”

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read